Using 18F- FDG,18F-DOPA and 68Ga-DOTATATE PET/CT in Detection and Evaluation of Response in Patients With NET Undergoing PRRT

• Conditions: Neuroendocrine Tumors

• Registration Number: NCT04622631
• Lead Sponsor: Dr. Nayruz Knaana

Brief Summary

the investigators will follow up after patients with neuroendocrine tumors who undergo PRRT treatment and evaluate the response for treatment using PET/CT with different tracers

Detailed Description

patients with suspected or biopsy proven NET will undergo imaging using a Combination of 18F- FDG , 18F-DOPA and 68Ga-DOTATATE PET/CT before the stat of PRRT . after two cycles of treatment another two PET/CT are done using 18F- FDG and 18F-DOPA and about 6-8 weeks from last treatment the patient will undergo PET/CT using 18F-DOPA .

Study Timeline

• Status Verified: 2020-10
• Study First Submitted: 2020-10-30
• Study Start: 2020-11
• Study First Submitted QC: 2020-11-09
• Last Update Submitted: 2020-11-09
• Study First Posted: 2020-11-10
• Last Update Posted: 2020-11-10
• Primary Completion: 2022-01
• Study Completion: 2023-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• patient with neuroendocrine tumor
• eligible for PRRT

Exclusion Criteria

• younger than 18 years old
• pregnancy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Number of participants with no response to Peptide Receptor Radionuclide Therapy (PRRT) treatment	7 months	patients who have no clinical and radiological improvement or worsening in clinical condition or radiologic findings (RECIST )
Number of participants with good response to Peptide Receptor Radionuclide Therapy (PRRT)	7 months	patients who have clinical and radiological improvement (using RECIST CRITERIA )

Trial Locations

Locations (1)

Sheba Medical Center; 🇮🇱 Ramat Gan, Israel